AZURITY PHARMACEUTICALS, INC. v. NOVITIUM PHARMA, LLC
1:23-cv-00163
Overview
Parties
Defendant
Novitium Pharma LLC Operating Company
Represented By
6 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., DE
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Plaintiff
Azurity Pharmaceuticals, Inc. Operating Company
Represented By
1 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Intervenor Defendant
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 13 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 11,040,023 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 11,141,405 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 11,173,141 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2022004754 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2016623101 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 9,669,008 B1 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 9,808,442 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,039,745 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,154,987 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,786,482 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,772,868 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,799,476 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,918,621 B2 | US Continuation / Sibling | View Official Patent → |
Azurity Pharmaceuticals, Inc. v. CoreRx, Inc.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US11040023
Enalapril formulations
|
Filed: 2021-01-15
Issued: 2021-06-22
|
Active (14.2 yrs remaining)
Expires: 2041-01-15
|
|
|
US11141405
Enalapril formulations
|
Filed: 2021-04-12
Issued: 2021-10-12
|
Active (9.3 yrs remaining)
Expires: 2036-03-25
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
11
Dispositive
9
Granted
4
Denied
0
Pending / Review
7
Motions by Category
Key Dispositive Motions & Rulings